DekaBank Deutsche Girozentrale Raises Stock Holdings in Zoetis Inc. (NYSE:ZTS)


Share on StockTwits

DekaBank Deutsche Girozentrale grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.9% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 224,968 shares of the company’s stock after purchasing an additional 6,237 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Zoetis were worth $36,486,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Jeppson Wealth Management LLC purchased a new stake in shares of Zoetis during the 3rd quarter valued at about $25,000. Graves Light Private Wealth Management Inc. purchased a new stake in shares of Zoetis during the 4th quarter valued at about $31,000. TRU Independence Asset Management 2 LLC purchased a new stake in shares of Zoetis during the 4th quarter valued at about $31,000. Encompass Wealth Advisors LLC purchased a new stake in shares of Zoetis during the 4th quarter valued at about $31,000. Finally, Arlington Partners LLC purchased a new stake in Zoetis in the 4th quarter worth approximately $32,000. 92.50% of the stock is owned by hedge funds and other institutional investors.

ZTS has been the subject of several analyst reports. Bank of America raised shares of Zoetis from a “neutral” rating to a “buy” rating and set a $180.00 target price for the company in a report on Monday, March 15th. Raymond James raised shares of Zoetis from a “market perform” rating to an “outperform” rating and set a $166.00 target price for the company in a report on Monday, March 15th. Finally, Credit Suisse Group increased their target price on shares of Zoetis from $197.00 to $203.00 in a report on Wednesday, February 17th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $170.08.

In other news, Director Robert W. Scully bought 7,590 shares of the stock in a transaction dated Friday, February 19th. The stock was purchased at an average cost of $164.68 per share, for a total transaction of $1,249,921.20. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Robert Edward Kelly sold 2,055 shares of the stock in a transaction that occurred on Thursday, April 1st. The shares were sold at an average price of $158.05, for a total value of $324,792.75. 0.17% of the stock is currently owned by corporate insiders.

ZTS stock opened at $157.88 on Thursday. Zoetis Inc. has a 1-year low of $121.50 and a 1-year high of $176.64. The company has a debt-to-equity ratio of 2.41, a current ratio of 3.47 and a quick ratio of 2.60. The company has a market capitalization of $75.02 billion, a price-to-earnings ratio of 46.85, a PEG ratio of 4.35 and a beta of 0.71. The business has a 50 day simple moving average of $155.41 and a two-hundred day simple moving average of $160.68.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, February 16th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.86 by $0.05. The firm had revenue of $1.81 billion during the quarter, compared to the consensus estimate of $1.73 billion. Zoetis had a return on equity of 63.89% and a net margin of 25.50%. During the same period in the prior year, the company earned $0.92 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 3.63 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 1st. Stockholders of record on Wednesday, April 21st will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Tuesday, April 20th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.63%. Zoetis’s dividend payout ratio is currently 27.47%.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More: Moving Average Convergence Divergence (MACD)

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.